75 related articles for article (PubMed ID: 15140582)
21. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
[TBL] [Abstract][Full Text] [Related]
24. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin.
Veach SA; Franks AM; Allan MC
Pharmacotherapy; 2007 May; 27(5):760-5. PubMed ID: 17461712
[TBL] [Abstract][Full Text] [Related]
25. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.
Riess FC; Poetzsch B; Madlener K; Cramer E; Doll KN; Doll S; Lorke DE; Kormann J; Mueller-Berghaus G
Thorac Cardiovasc Surg; 2007 Jun; 55(4):233-8. PubMed ID: 17546553
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
27. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Dong X; Gu R; Zhu X; Gan H; Liu J; Jin J; Meng Z; Dou G
Eur J Pharm Sci; 2018 Aug; 121():166-177. PubMed ID: 29802897
[TBL] [Abstract][Full Text] [Related]
28. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Greinacher A; Lubenow N; Eichler P
Circulation; 2003 Oct; 108(17):2062-5. PubMed ID: 14568897
[TBL] [Abstract][Full Text] [Related]
29. [Determination of recombinant hirudin in urine of rat by spectrophotometric method].
Jiang SY; Jiao J; Lu J; Xu YP; Dou GF
Guang Pu Xue Yu Guang Pu Fen Xi; 2013 May; 33(5):1327-30. PubMed ID: 23905345
[TBL] [Abstract][Full Text] [Related]
30. Retention of lepirudin at the tip of a silicone catheter: a better catheter flush solution?
Horne MK; Inkellis E
Support Care Cancer; 2004 Apr; 12(4):278-81. PubMed ID: 14968353
[TBL] [Abstract][Full Text] [Related]
31. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour.
Markwardt F; Richter M; Walsmann P; Riesener G; Paintz M
Biomed Biochim Acta; 1990; 49(10):1103-8. PubMed ID: 1706917
[TBL] [Abstract][Full Text] [Related]
32. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
[TBL] [Abstract][Full Text] [Related]
33. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
34. The anticoagulant and antithrombotic properties of hirudins.
Märki WE; Wallis RB
Thromb Haemost; 1990 Nov; 64(3):344-8. PubMed ID: 2096484
[No Abstract] [Full Text] [Related]
35. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Jung R; MacLaren R; Fish DN
Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
[TBL] [Abstract][Full Text] [Related]
37. Optimizing management of hirudin anticoagulation.
Measday MA; Zucker ML; Pan CM; LaDuca FM
J Extra Corpor Technol; 2005 Mar; 37(1):66-70. PubMed ID: 15804161
[TBL] [Abstract][Full Text] [Related]
38. Effect of lepirudin on the international normalized ratio.
Stephens JL; Koerber JM; Mattson JC; Smythe MA
Ann Pharmacother; 2005 Jan; 39(1):28-31. PubMed ID: 15590880
[TBL] [Abstract][Full Text] [Related]
39. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
40. Hirudin as alternative anticoagulant--a historical review.
Markwardt F
Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
